anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Venous thromboembolism (VTE), comprising deep venous thrombosis (DVT), pulmonary embolism (PE), or both, is a life-threatening complication in postoperative patients. This cross-sectional study was aimed to investigate the incidence, associated risk factors, prophylaxis, treatment, and outcomes of VTE in a large clinical neurosurgery center in China. 9010 patients underwent neurosurgery procedure were included. Distribution of age, sex, whether received PICC during perioperative period, and some special primary diseases are significantly different between VTE and non-VTE patients. Student's test and chi-square test were performed for analyses. We investigated VTE incidence, risk factors, prophylaxes, treatment and outcomes in postoperative neurosurgical patients, and summarized the VTE susceptible population of the patients, providing a VTE patient profile for neurosurgeons to concern.
To explore the learning curve of robot-assisted laparoscopic pyeloplasty (RALP) in children. The clinical data, surgical information, and postoperative complications of consecutive cases of RALP performed by the same surgeon in Shanghai Children's Hospital from January 2014 to July 2020 were retrospectively analyzed; the surgeon is a senior pediatric urologists who is proficient in laparoscopic pyeloplasty; the data consist of console time (CT), suture method when anastomosing ureteropelvic junction (UPJ), number of stitches (N), anastomosis time per stitch (tn), the average suture time per stitch (T) = (suture time of first stitch (t1) + second stitch (t2) + … + tn)/N, postoperative complications, and surgical outcome. The learning curve was depicted by cumulative sum method (CUSUM) and validated by cumulative method (CUM). Of the 88 cases, 64 cases were included in present study. Median CT was 104 (83-117) min, mean T was 109 ± 17 s. There were ten cases of Clavien-Dindo Grade I complication and two cases of Clavien-Dindo Grade IIIb complication. The median follow-up time was 237 (87-627) days. The learning curve of CT has three stages, with inflection points at 11th and 57th case, and T has two stages, with inflection points at 19th case. There was a statistically significant difference between the console time and length of stay on both sides of the inflection point (P < 0.05), but there was no statistically significant difference in age, gender, etiology, clinical manifestation, surgical outcome, and complication (P > 0.05). For a senior pediatric urologists who is proficient in laparoscopic pyeloplasty, the learning curve of RALP can be divided into three stages, preliminary exploration stage, mastery stage, and proficiency stage. It takes about 11 cases to achieve the mastery stage, and it takes about 57 cases to achieve the proficiency stage. The learning curve focused on the suture technique of the surgeon is divided into two stages, and after a learning period of 19 cases, it will reach the proficiency stage of suturing UPJ.
PURPOSE:To provide a gelatin capsule composition containing a water-swelling component, having excellent shape-retainability and solubility and safe to human body. CONSTITUTION:A water-swelling component preferably selected from clay minerals (e.g. bentonite or montmorillonite), starch and water-absorbing resins (e.g. polyacrylic acid salt or CMC) is compounded in an amount of 0.1-10 wt.% (based on total composition) to a composition produced by using gelatin as main component and adding glycerol and water as a plasticizer. Compounding of an organic acid such as malic acid, tartaric acid or lactic acid to the composition is preferable to attain improved effect. If necessary, the composition is further compounded with colorant, preservative and ultraviolet absorber. The composition keeps its original solubility even by being left standing at room temperature or high temperature over a long period.
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for altering cell functions and to provide a method especially as a therapeutic treatment and/or a prophylactic treatment for neurodegenerative diseases.  <P>SOLUTION: The composition comprising Sel-Plex is administered under conditions in which the expression of a complement gene, the expression of a cathepsin gene, the expression of a presenilin gene or the expression of a nicastrin gene is reduced in the cerebral cortex. The composition comprising the Sel-Plex may contain sodium selenite and an antioxidant. The composition may simultaneously be administered with another Alzheimer therapeutic agent. The composition has effects on treatment or prophylaxis of Alzheimer's disease, Parkinson's disease, Huntington's disease, etc.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Heparin is a blood thinning medication that is often prescribed to treat or prevent blood clots. HIT is a life-threatening immune disorder that occurs in 1 to 3% of people who receive heparin. In this disorder, heparin does the opposite of what it is supposed to do: it promotes new blood clot formation, rather than preventing it. In people with HIT, the immune system triggers a response against heparin, leading to the destruction of platelets and a low platelet count, which is known as thrombocytopenia. Symptoms usually occur between 5 to 14 days after starting heparin therapy. Isolated HIT is a form of the condition that occurs when people have a low platelet count, but there is no sign of a blood clot, or thrombosis. Several small research studies have shown that at the time of isolated HIT diagnosis, between 15 to 50% of people actually have asymptomatic thrombosis, which means that they are not showing any signs of a blood clot, but in fact have one. In the month following HIT diagnosis, up to 50% of people experience symptomatic thrombosis, which means that they are showing signs of a blood clot. It is not currently known how to best treat isolated HIT and how to test for unrecognized blood clots. This study will use ultrasound imaging to evaluate the number of people who have asymptomatic thrombosis at the time of isolated HIT diagnosis and to determine the rate of symptomatic and asymptomatic thrombosis in the following month. The results of this study will assist researchers in assessing current approaches to treating isolated HIT and in designing new clinical trials. By exploring the use of non-invasive evaluation techniques in people with HIT, thrombosis research in HIT will move forward, similar to thrombosis research in other medical conditions.

This 29-day study will enroll hospital patients who have a diagnosis of HIT but show no signs of a blood clot at the time of HIT diagnosis. On Day 1, participants will undergo blood collection and an ultrasound. While participants are in the hospital, study researchers will review participants' medical records on a daily basis to collect data on current medications, medication compliance, symptoms, bleeding, thrombosis complications, and laboratory test results. Once participants leave the hospital, this data will be collected at least once a week through phone calls with the participant and/or the treating physician. On Day 29, participants will undergo a repeat ultrasound and blood collection.
BACKGROUND: Oncogenic types of human Papillomavirus (HPV) infection cause substantial morbidity and mortality in Nigeria. Nigeria has low cervical cancer screening and vaccination rates, suggesting the need for community engagement to enhance reach and uptake. We organised a designathon to identify community-led, innovative approaches to promote HPV screening and vaccination for women and girls, respectively, in Nigeria. A designathon is a three-phase participatory process informed by design thinking that includes the preparation phase that includes soliciting innovative ideas from end-users, an intensive collaborative event to co-create intervention components, and follow-up activities.
METHODS: We organised a three-phase designathon for women (30-65yrs) and girls (11-26yrs) in Nigeria. First, we launched a national crowdsourcing open call for ideas on community-driven strategies to support HPV screening among women and vaccination among girls. The open call was promoted widely on social media and at in-person gatherings. All eligible entries were graded by judges and 16 exceptional teams (with 4-6members each). All six geo-political zones of Nigeria were invited to join an in-person event held over three days in Lagos to refine their ideas and present them to a panel of expert judges. The ideas from teams were reviewed and scored based on relevance, feasibility, innovation, potential impact, and mother-daughter team dynamics. We present quantitative data on people who submitted and themes from the textual submissions.
RESULTS: We received a total of 612 submissions to the open call from mother-daughter dyads. Participants submitted ideas via a website designated for the contest (n = 392), in-person (n = 99), email (n = 31), or via an instant messaging application (n = 92). Overall, 470 were eligible for judging after initial screening. The average age of participants for daughters was 19 years and 39 years for mothers. Themes from the top 16 proposals included leveraging local leaders (5/16), faith-based networks (4/16), educational systems (4/16), and other community networks (7/16) to promote awareness of cervical cancer prevention services. After an in-person collaborative event, eight teams were selected to join an innovation training boot camp, for capacity building to implement ideas.
CONCLUSIONS: Innovative strategies are needed to promote HPV screening for mothers and vaccination for girls in Nigeria. Our designathon was able to facilitate Nigerian mother-daughter teams to develop cervical cancer prevention strategies. Implementation research is needed to assess the effectiveness of these strategies.
The 2022 WHO Classification revised the diagnostic criteria of CMML and included the variant, formerly known as oligomonocytic CMML (O-CMML), into the CMML disease. CMML is currently subtyped into MD-CMML and MP-CMML. In a recent study, Castaño-Díez et al. showed that the newly included O-CMML has unique clinical features and is an independent favourable risk factor, and proposed to view O-CMML as an independent subtype of CMML, parallel to MD-CMML and MP-CMML. Commentary on: Castaño-Díez et al. Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic. Br J Haematol 2024;204:892-897.
The invention discloses a method for manufacturing anti-freezing and anti-cracking type PVC gloves. A formula for manufacturing traditional PVC gloves is improved through the method. The method includes the steps that after lip rolling, beewax is added to ultramicro wall broken powder of angelica sinensis, ramulus cinnamomi, asarum, ginger, folium artemisiae argyi and cinnamon, and after powder spraying, the gloves are formed through powder removal, die removal and powder falling. The gloves have the good anti-freezing and anti-cracking effects. The gloves integrate essences of nutritional ingredients of angelica sinensis, ramulus cinnamomi, asarum, ginger, folium artemisiae argyi and the like, when the gloves are used, the temperature of the hands rises, muscles are relaxed, blood circulation is stimulated, pores open, dirt is discharged along with breath of skin, the nutritional ingredients gradually and deeply nourish the hands, and then the hands of users are further cared. The gloves are environmentally friendly and sanitary, and brings convenience for people, the hands are further cared, and the gloves have the advantages of being high in heat stability, free of causing allergy, safe to use, and capable of resisting static.
First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
A technique manages medical image data. The technique involves receiving an original medical imaging study that includes a set of medical images and embedded protected patient information. The technique further involves performing a protected patient information removal operation which generates a cloud-storable medical imaging study from the original medical imaging study. The cloud-storable medical imaging study includes the set of medical images but omitting the embedded protected patient information. The technique further involves storing the cloud-storable medical imaging study in a cloud-based medical image repository among other cloud-storable medical image studies. The cloud-based medical image repository is external to the computerized device and public network accessible.
After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
OBJECTIVE: (Cardiac) interoception was long considered a key mechanism behind symptom perception in persistent somatic symptoms (PSS). In this study, we aimed to extend earlier findings to clarify this potential interoceptive mechanisms of PSS.
METHODS: A cross-sectional sample of 251 participants (23.1% with self-reported functional somatic syndrome) completed a laboratory study with two cardioceptive accuracy tasks (Schandry task and a new cardiac signal detection task) and multiple questionnaires. Somatic symptom distress and associated constructs were assessed with the PHQ-15, as well as with a novel multidimensional questionnaire measure (HiTOP-SF1) derived from the somatoform spectrum of the Hierarchical Taxonomy of Psychopathology (HiTOP). Correlations (frequentist and Bayesian) and structural equation modelling (SEM) helped further investigate the interplay between these variables.
RESULTS: There were no significant correlations between measures of interoception and somatic symptom distress. Self-report and behavioral cardioceptive accuracy measures did not correlate significantly. No significant covariances emerged between diagnostic tools and cardioceptive accuracy; Bayesian analyses supported the lack of association between interoception and symptom perception.
CONCLUSIONS: Cardiac interoception (specifically cardioceptive accuracy) unlikely represents a key mechanism in PSS etiology. We recommend investigating other factors in PSS.
Performing the first ultrasound scan on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression.
An appetite-suppressing agent or an apparatus for dieting or suppressing appetite by which the appetite of a user can be safely suppressed neither placing any physical or mental burden to the user nor exhibiting any side effect, i.e., the appetite can be appropriately suppressed without requiring excessive efforts or burden and a slimming effect can be safely and healthfully established. An appetite-suppressing agent which comprises, as the active ingredientz(s), Vernonia cinerea optionally together with an extract of mulberry with an aqueous solvent. A dieting method which comprises evaporating the liquid ingredients of the appetite suppressing agent and allowing a diet wisher to aspirate the vapor thus generated with a breathing device. Since the active ingredients, which are odorless, are not orally absorbed via the digestive organs but directly incorporated into the blood via respiratory organs such as the lungs or the nasal mucosa. Thus, the sense of being on a diet can be supported via the central nerve and the appetite of a diet wisher with a need for body weight loss can be suppressed to thereby achieve a slimming effect. On the other hand, no slimming effect is achieved on those who having no sense of attitude toward dieting.
A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity. The stomatological composition includes at least one selected from the group consisting of lipase, protease and the antibody obtained from the hen egg yolk, citric acid and a metal salt of citric acid. A total amount of the lipase, the protease and the antibody obtained from the hen egg yolk is in the range of 0.001 to 10 wt %. When an amount of the citric acid is defined as “A” [wt %] and an amount of the metal salt of citric acid is defined as “B” [wt %], the following relation is satisfied: 0.005≦A/B≦1. Further, the stomatological composition of the present invention includes a polyglyceryl fatty acid ester or an amino acid-based ampholytic surfactant as a surfactant. Further, the stomatological composition of the present invention includes a collagen.
OBJECTIVE: The increasing prevalence of and inequities in childhood obesity demand improved access to effective treatment. The SmartMoves curriculum used in Bright Bodies, a proven-effective, intensive health behavior and lifestyle treatment (IHBLT), was disseminated to ≥30 US sites from 2003 to 2018. We aimed to identify barriers to and facilitators of IHBLT implementation/sustainment.
METHODS: We surveyed and interviewed key informants about experiences acquiring/implementing SmartMoves. In parallel, we analyzed and then integrated survey findings and themes from interviews using the constant comparative method.
RESULTS: Participants from 16 sites (53%) completed surveys, and 12 participants at 10 sites completed interviews. The 11 sites (63%) that implemented SmartMoves varied in both use of training opportunities/materials and fidelity to program components. In interviews, demand for obesity programming, organizational priorities, and partnerships facilitated implementation. Seven sites discontinued SmartMoves prior to the COVID-19 pandemic. Funding insecurity and insufficient staffing emerged as dominant barriers to implementation/sustainment discussed by all interviewees, and some also noted participants' competing demands and the program's fit with population as challenges.
CONCLUSIONS: System- and organizational-level barriers impeded sustainment of an evidence-based IHBLT program. Adequate funding could enable sufficient staffing and training to promote fidelity to the intervention's core functions and adaptation to fit local populations/context.
The invention relates to cells for adoptive cell therapy, e.g., adoptive immunotherapy. The cells include macrophages in which the iPLA 2 β gene is disrupted. Also provided are methods and uses of the cells, such as in adoptive therapy in the treatment or prevention of type 1 diabetes (T1D). Also provided are methods for engineering, preparing, and producing the cells, and compositions containing the cells. In some aspects, the provided embodiments provide an improved composition and method for the treatment of T1D. Among the cells disclosed herein are those in which certain genes and/or gene products have been disrupted, modified and/or repressed, in particular via disruption that impairs or reduces expression of iPLA 2 β.
The present invention relates to an oil composition which is prepared from 50% of O, O-diethyl-O-alpha-cyano-phenylidene-amine-thiono-phosphate ester (phoxim), a penetrating agent and an emulsifying agent. When only the insecticide is used for treating rabbit mite disease, the cure can be obtained after a plurality of treating times. Thus, the operation is troubled. The present invention adding a main medical agent which is 50% of phoxim into a penetrating agent (coal oil) and an emulsifying agent (prepared from compounding peanut oil, rapeseed oil, etc.,) according to the proportion from 0.2% to 0.6%. The capacities of the main medical agent for killing the mite and ova are obviously improved. 100% cure can be obtained by one time of medication. The present invention has obvious social and economic benefits.
PURPOSE: To evaluate the method of thrombin injection under B-flow and ultrasound guidance (BUGTI) for the treatment of pseudoaneurysms.
MATERIALS AND METHODS: Twenty-one patients suffering from pseudoaneurysm (PSA) were retrospectively reviewed at the First Affiliated Hospital of Nanjing Medical University in Nanjing, China, from January 2018 to August 2019. The patients were treated using an ultrasound-guided injection of thrombin (500 IU/mL) combined with B-mode blood flow imaging (B-flow). The information on the PSA, including the size of the arterial rupture and sac, flow rate, thrombin dose, and treatment outcome, was recorded during the procedure. Follow-up evaluation was performed at 1, 3, and 6 months after the treatment. Pearson's correlation analysis was performed among the characteristics of PSA and the dose of thrombin.
RESULT: The age of patients ranged from 34 to 80 years and averaged 62.8 years. The maximum cross-sectional area of PSA ranged from 208 to 1148 mm2. All patients were treated with thrombin injections. The dose of thrombin ranged from 300 to 1667 IU. No reperfusions were detected at follow-up 6 months, and the BUGTI treatment was successful in all 21 cases. Pearson's correlation analysis demonstrated that the dose of thrombin was positively correlated with the width (r = 0.449, p < .05) and maximum cross-sectional area (r = 0.504, p < .05) of PSA.
CONCLUSION: Thrombin injection under B-flow and ultrasound guidance is a rapid and effective treatment for PSA. Additionally, the sac size could be used to estimate the dose of thrombin.
Mitochondria are essential organelles that play critical roles in energy metabolism, apoptosis and various cellular processes. Accumulating evidence suggests that mitochondria are also involved in cancer development and progression. The mitochondrial unfolded protein response (UPRmt) is a complex cellular process that is activated when the protein-folding capacity of the mitochondria is overwhelmed. The core machinery of UPRmt includes upstream regulatory factors, mitochondrial chaperones and proteases. These components work together to eliminate misfolded proteins, increase protein-folding capacity, and restore mitochondrial function. Recent studies have shown that UPRmt is dysregulated in various cancers and contributes to tumor initiation, growth, metastasis, and therapeutic resistance. Considering the pivotal role of the UPRmt in oncogenesis, numerous compounds and synthetic drugs targeting UPRmt-related components induce cancer cell death and suppress tumor growth. In this review, we comprehensively summarize recent studies on the molecular mechanisms of UPRmt activation in C. elegans and mammals and elucidate the conceptual framework, functional aspects, and implications of the UPRmt for cancer therapy. In summary, we paint a developmental landscape of the UPRmt in different types of cancer and offer valuable insights for the development of novel cancer treatment strategies by targeting the UPRmt.